Efficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study

被引：0

作者：

Fox, Robert ^{[1
]}

Kappos, Ludwig ^{[2
,3
,4
,5
]}

Burcklen, Michel ^{[6
]}

Freedman, Mark ^{[7
,8
]}

Havrdova, Eva ^{[9
]}

Hennessy, Brian ^{[6
]}

Hohlfeld, Reinhard ^{[10
]}

Lublin, Fred ^{[11
]}

Montalban, Xavier ^{[12
,13
]}

Pozzilli, Carlo ^{[14
]}

Scherz, Tatiana ^{[6
]}

Linscheid, Philippe ^{[6
]}

Pirozek-Lawniczek, Magdalena ^{[6
]}

Kracker, Hilke ^{[6
]}

Sprenger, Till ^{[2
,3
,4
,5
,15
]}

机构：

[1] Cleveland Clin, Cleveland, OH 44106 USA

[2] Univ Hosp Basel, Neurol Clin & Policlin, Dept Med, Basel, Switzerland

[3] Univ Hosp Basel, Neurol Clin & Policlin, Dept Clin Res, Basel, Switzerland

[4] Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed, Basel, Switzerland

[5] Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed Engn, Basel, Switzerland

[6] Actel Pharmaceut Ltd, Allschwil, Switzerland

[7] Univ Ottawa, Ottawa, ON, Canada

[8] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[9] Charles Univ Prague, Prague, Czech Republic

[10] Ludwig Maximilians Univ Munchen, Inst Clin Neuroimmunol, Munich, Germany

[11] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[12] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[13] Vall dHebron Univ Hosp, Multiple Sclerosis Ctr Catalonia, Barcelona, Spain

[14] Sapienza Univ Rome, S Andrea MS Ctr, Rome, Italy

[15] DKD HELIOS Klin Wiesbaden, Wiesbaden, Germany

来源：

NEUROLOGY | 2020年 / 94卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

3972

引用

页数：5

共 50 条

[1] Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing multiple sclerosis: results of the randomized, active-controlled, double-blind, parallel-group phase 3 OPTIMUM study
Kappos, L.
Burcklen, M.
Freedman, M. S.
Fox, R.
Havrdova, E. K.
Hennessy, B.
Hohlfeld, R.
Lublin, F.
Montalban, X.
Pozzilli, C.
Scherz, T.
Linscheid, P.
Pirozek-Lawniczek, M.
Kracker, H.
Sprenger, T.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 30 - 31
[2] Safety and Tolerability of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study
Sprenger, Till
Burcklen, Michel
Freedman, Mark S.
Fox, Robert
Havrdova, Eva K.
Hennessy, Brian
Hohlfeld, Reinhard
Lublin, Fred
Montalban, Xavier
Pozzilli, Carlo
Vaclavkova, Andrea
Scherz, Tatiana
Linscheid, Philippe
Pirozek-Lawniczek, Magdalena
Kracker, Hilke
Kappos, Ludwig
NEUROLOGY, 2020, 94 (15)
[3] Cardiac safety of ponesimod in relapsing multiple sclerosis in the randomized, active-controlled, double-blind, parallel-group phase 3 optimum study
Sprenger, T.
Vaclavkova, A.
Burcklen, M.
Freedman, M.
Fox, R.
Havrdova, E.
Hennessy, B.
Walter, V.
Hohlfeld, R.
Lublin, F.
Montalban, X.
Pozzilli, C.
Scherz, T.
Linscheid, P.
Pirozek-Lawniczek, M.
Kracker, H.
Camm, A.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 211 - 211
[4] Ponesimod Versus Teriflunomide in Relapsing Multiple Sclerosis: Efficacy Results from the OPTIMUM Phase 3 Randomised, Double-Blind Superiority Study
Fox, R.
Burcklen, M.
Freedman, M. S.
Havrdova, F. K.
Hennessy, B.
Hohlfeld, R.
Lublin, F.
Montalban, X.
Pozzilli, C.
Scherz, T.
Linscheid, P.
Pirozek-Lawniczek, M.
Kracker, H.
Sprenger, T.
Kappos, L.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 338 - 338
[5] Results of the Phase 3 OPTIMUM Study of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis
Jones, R.
Turkoz, I.
Ait-Tihyaty, M.
DiBernardo, A.
Houtchens, M.
Havrdova, E.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 59 - 60
[6] Ponesimod compared with teriflunomide in female patients of childbearing age with relapsing multiple sclerosis: Results of the phase 3 OPTIMUM study
Jones, R. R.
Turkoz, I.
Ait-Tihyaty, M.
DiBernardo, A.
Houtchens, M.
Havrdova, E. K.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 460 - 461
[7] Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
Kappos, Ludwig
Fox, Robert J.
Burcklen, Michel
Freedman, Mark S.
Havrdova, Eva K.
Hennessy, Brian
Hohlfeld, Reinhard
Lublin, Fred
Montalban, Xavier
Pozzilli, Carlo
Scherz, Tatiana
D'Ambrosio, Daniele
Linscheid, Philippe
Vaclavkova, Andrea
Pirozek-Lawniczek, Magdalena
Kracker, Hilke
Sprenger, Till
JAMA NEUROLOGY, 2021, 78 (05) : 558 - 567
[8] The POINT study: a randomized, double-blind, parallel-group, add-on, superiority phase 3 study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate
Kappos, L.
Lindenstrom, E.
Freedman, M.
Fox, R.
Havrdova, E.
Hennessy, B.
Hohlfeld, R.
Lemle, A.
Lublin, F.
Montalban, X.
Sprenger, T.
Pozzilli, C.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 271 - 272
[9] Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 9-month double-blind active extension of the multicenter, randomized, double-blind, parallel-group placebo-controlled study
Comi, Giancarlo
Abramsky, O.
Arbizu, T.
Boyko, Alexey
Gold, Ralf
Havrdova, Eva
Komoly, Samuel
Selmaj, Krzysztof
Sharrack, Basil
Filippi, Massimo
MULTIPLE SCLEROSIS, 2008, 14 : S37 - S38
[10] Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study
Jones, Robyn R.
Turkoz, Ibrahim
Ait-Tihyaty, Maria
Dibernardo, Allitia
Houtchens, Maria K.
Havrdova, Eva Kubala
JOURNAL OF WOMENS HEALTH, 2024, 33 (04) : 480 - 490

← 1 2 3 4 5 →